Cargando…
New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
A new sigma-2 (σ2) receptor ligand (FA4) was efficiently synthesized and evaluated for cytotoxic, proapoptotic, and antimigratory activity on pancreatic ductal adenocarcinoma (PDAC) primary cell cultures, which restrained the aggressive and chemoresistant behavior of PDAC. This compound showed relev...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911630/ https://www.ncbi.nlm.nih.gov/pubmed/35268783 http://dx.doi.org/10.3390/molecules27051682 |
_version_ | 1784666866968428544 |
---|---|
author | Anobile, Dario P. Niso, Mauro Puerta, Adrian Fraga Rodrigues, Stephanie M. Abatematteo, Francesca S. Avan, Amir Abate, Carmen Riganti, Chiara Giovannetti, Elisa |
author_facet | Anobile, Dario P. Niso, Mauro Puerta, Adrian Fraga Rodrigues, Stephanie M. Abatematteo, Francesca S. Avan, Amir Abate, Carmen Riganti, Chiara Giovannetti, Elisa |
author_sort | Anobile, Dario P. |
collection | PubMed |
description | A new sigma-2 (σ2) receptor ligand (FA4) was efficiently synthesized and evaluated for cytotoxic, proapoptotic, and antimigratory activity on pancreatic ductal adenocarcinoma (PDAC) primary cell cultures, which restrained the aggressive and chemoresistant behavior of PDAC. This compound showed relevant antiproliferative activity with half maximal inhibitory concentration (IC50) values ranging from 0.701 to 0.825 μM. The cytotoxic activity was associated with induction of apoptosis, resulting in apoptotic indexes higher than those observed after exposure to a clinically relevant concentration of the gemcitabine, the first-line drug used against PDAC. Interestingly, FA4 was also able to significantly inhibit the migration rate of both PDAC-1 and PDAC-2 cells in the scratch wound-healing assay. In conclusion, our results support further studies to improve the library of thiosemicarbazones targeting the σ-2 receptor for a deeper understanding of the relationship between the biological activity of these compounds and the development of more efficient anticancer compounds against PDAC. |
format | Online Article Text |
id | pubmed-8911630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89116302022-03-11 New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 Anobile, Dario P. Niso, Mauro Puerta, Adrian Fraga Rodrigues, Stephanie M. Abatematteo, Francesca S. Avan, Amir Abate, Carmen Riganti, Chiara Giovannetti, Elisa Molecules Article A new sigma-2 (σ2) receptor ligand (FA4) was efficiently synthesized and evaluated for cytotoxic, proapoptotic, and antimigratory activity on pancreatic ductal adenocarcinoma (PDAC) primary cell cultures, which restrained the aggressive and chemoresistant behavior of PDAC. This compound showed relevant antiproliferative activity with half maximal inhibitory concentration (IC50) values ranging from 0.701 to 0.825 μM. The cytotoxic activity was associated with induction of apoptosis, resulting in apoptotic indexes higher than those observed after exposure to a clinically relevant concentration of the gemcitabine, the first-line drug used against PDAC. Interestingly, FA4 was also able to significantly inhibit the migration rate of both PDAC-1 and PDAC-2 cells in the scratch wound-healing assay. In conclusion, our results support further studies to improve the library of thiosemicarbazones targeting the σ-2 receptor for a deeper understanding of the relationship between the biological activity of these compounds and the development of more efficient anticancer compounds against PDAC. MDPI 2022-03-04 /pmc/articles/PMC8911630/ /pubmed/35268783 http://dx.doi.org/10.3390/molecules27051682 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Anobile, Dario P. Niso, Mauro Puerta, Adrian Fraga Rodrigues, Stephanie M. Abatematteo, Francesca S. Avan, Amir Abate, Carmen Riganti, Chiara Giovannetti, Elisa New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 |
title | New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 |
title_full | New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 |
title_fullStr | New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 |
title_full_unstemmed | New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 |
title_short | New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 |
title_sort | new pharmacological strategies against pancreatic adenocarcinoma: the multifunctional thiosemicarbazone fa4 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911630/ https://www.ncbi.nlm.nih.gov/pubmed/35268783 http://dx.doi.org/10.3390/molecules27051682 |
work_keys_str_mv | AT anobiledariop newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4 AT nisomauro newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4 AT puertaadrian newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4 AT fragarodriguesstephaniem newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4 AT abatematteofrancescas newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4 AT avanamir newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4 AT abatecarmen newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4 AT rigantichiara newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4 AT giovannettielisa newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4 |